KKR (KKR) to Acquire ReSearch Pharmaceutical Services (RPS), Inc.
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
KKR (NYSE: KKR) announced the signing of a definitive agreement to acquire ReSearch Pharmaceutical Services Inc. (“RPS”), a leading global contract research organization (CRO), from Warburg Pincus. This follows an announcement on June 24, 2013 in which KKR announced the acquisition of another leading CRO, PRA International (“PRA”). Terms of the transaction were not disclosed. Upon close of both of the transactions, PRA and RPS will merge, with PRA Chief Executive Officer Colin Shannon leading the combined enterprise.
Help employers find you! Check out all the jobs and post your resume.
KKR (NYSE: KKR) announced the signing of a definitive agreement to acquire ReSearch Pharmaceutical Services Inc. (“RPS”), a leading global contract research organization (CRO), from Warburg Pincus. This follows an announcement on June 24, 2013 in which KKR announced the acquisition of another leading CRO, PRA International (“PRA”). Terms of the transaction were not disclosed. Upon close of both of the transactions, PRA and RPS will merge, with PRA Chief Executive Officer Colin Shannon leading the combined enterprise.
Help employers find you! Check out all the jobs and post your resume.